Group 1 - The core viewpoint of the article is that Weimou Biotechnology (Zhejiang) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor [1] - The company has two core products, VVN461 (high dose) and VVN001, with VVN461 being a novel dual-target inhibitor for Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) [1] - VVN461 (high dose) is a high-dose formulation of VVN461 eye drops, with potency reaching nanomolar levels [1] Group 2 - The company was established in 2016 and focuses on the ophthalmology sector, aiming to become a global leader in the development and commercialization of innovative ophthalmic therapies [4] - In addition to its core products, the company has six other candidate drugs, three of which are in clinical stages as of the last feasible date [1]
新股消息 | 维眸生物递表港交所
智通财经网·2026-02-13 03:24